ClinicalTrials.gg
CompletedNCT01507181Updated Feb 8, 2017Results posted

Ketamine For Suicidal Ideation

A Phase 4 interventional study of Ketamine and Midazolam in Suicidal Ideation, sponsored by James Murrough. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by James Murrough · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies testing ketamine in Suicidal Ideation — 8 open to participants now, 9 under way, 3 of them phase 3. Ketamine · Suicidal Ideation.

Enrollment
17th of 36
24 · median 22
Started
2012
with 3 others
Phase 4
8 of 36
1 open now
Registered
1st of 36
by date

Among the 36 studies testing ketamine in Suicidal Ideation, this one is the 17th largest by enrollment, is one of 4 that started in 2012, is one of 8 in phase 4, and was the 1st registered.

Suicidal Ideation

570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.

Browse Suicidal Ideation studies →

Open to participants now

8 of the 36 studies testing ketamine in Suicidal Ideation are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ketamine in Suicidal Ideation, or all of them as a file.
02

Study summary

This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).

Read the detailed description

Depression is a debilitating disorder that affects 12-20% of population and is among the top five leading causes of burden of disease worldwide (Kruijshaar ME 2005). Suicide associated with depression and other psychiatric disorders is a pervasive public health problem and results in almost one million deaths per year. Unfortunately, current treatments for severe depression have limited efficacy for suicidality, specifically due to the slow time course of change in suicidal thoughts. Recently ketamine, a glutamate-modulating agent, was shown to have antidepressant and anti-suicidal effect in outpatient depressed patients. The proposed study will test the ability of a single sub-anesthetic intravenous (IV) dose of the glutamate NMDA receptor antagonist, ketamine, to provide rapid decrease in suicidal ideation (SI) in patients hospitalized with SI. In this randomized parallel-arm placebo controlled trial, ketamine is compared to midazolam, which is expected to mimic some of the acute subjective effects of ketamine but not have any sustained antidepressant effects.

Specific Aim 1: To determine feasibility and tolerability of a single low-dose IV infusion of ketamine in patients with prominent SI and elevated risk for suicide.

Hypothesis 1: Ketamine administration will be feasible and well tolerated in patients admitted to a psychiatric hospital with SI.

Specific Aim 2: To test the efficacy of a single IV dose of ketamine, compared to an anesthetic control condition (midazolam), to rapidly reduce SI in a controlled hospital setting.

Hypothesis 2: Ketamine will be associated with significant and rapid reductions in SI and depressive symptoms within 24 hours.

This study will test the rapid anti-suicidal effect of a single IV dose of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine in suicidality compared with the clinical response to a single IV dose of the short-acting benzodiazepine midazolam. Midazolam is able to induce transient neuropsychiatric effects mimicking ketamine and therefore is expected to protect the integrity of the blind. Participants will continue to receive standard treatment for their psychiatric condition throughout the trial. This unique "proof-of-concept" study in suicidal patients will be conducted over three-year period.

03

Conditions studied

  • Suicidal Ideation

Keywords

  • suicidal ideation
  • major depression
  • treatment resistant
  • ketamine
  • glutamate
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking Male or female patients, 18-80 years
  • Patients have voluntarily admitted themselves to an inpatient psychiatric unit at MSH or, regarding the outpatient population, have suicidal ideation without intent to harm themselves
  • Women of must have a negative pregnancy test
  • Clinically significant suicidal ideation and score of ≥4 on MADRS item 10 for suicidality
  • Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an document

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of schizophrenia or other primary psychotic disorder
  • Current presence of psychotic symptoms
  • Lifetime history of a clearly established psychotic episode
  • Established diagnosis of Schizoid, Schizotypal or Paranoid personality disorder
  • Urine toxicology screen positive for drugs of abuse on admission
  • Substance abuse or dependence within the preceding 1 month
  • Anticipated discharge within 7 days of study enrollment (for patients in the inpatient arm)
  • Women who plan to become pregnant, are pregnant or are breast-feeding
  • Concurrent course of electroconvulsive therapy (ECT)
  • Any unstable medical illness including hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease
  • abnormal findings of laboratory parameters, physical examination, or
  • The presence of any known or suspected to midazolam or ketamine including, but not limited to, known allergic reactions to these agents or acute intermittent porphyria
  • Uncontrolled hypertension, defined as BP systolic >160 or BP diastolic >100 on medications
  • Arrhythmia requiring medication
  • Severe coronary artery disease, defined as Canadian Cardiovascular Status III or IV
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Ketamine

    single dose IV ketamine, .5mg/kg

    Drug: Ketamine

  • Placebo comparator
    Midazolam

    single dose IV midazolam, .45mg/kg

    Drug: Midazolam

Interventions

  • single dose IV ketamine, .5mg/kg infused over 40 minutes

    Also known as: N-methyl-D-aspartate (NMDA) glutamate receptor antagonist

  • DrugMidazolam

    single dose IV midazolam, .45mg/kg infused over 40 minutes

06

What researchers measure

Primary outcomes

  1. Change in Beck Scale for Suicidal Ideation (BSSI)

    Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.

    Time frame: baseline and 24 hours post infusion

  2. Change in Beck Scale for Suicidal Ideation (BSSI)

    Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.

    Time frame: baseline and 48 hours post infusion

Secondary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.

    Time frame: up to 7 days post infusion

  2. Suicidality Item of the MADRS (MADRS-SI)

    The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide.

    Time frame: 24 hours post infusion

  3. The Young Mania Rating Scale (YMRS)

    An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.

    Time frame: baseline, 40 minutes post infusion, 240 minutes post infusion

  4. The Brief Psychiatric Rating Scale (BPRS)

    The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49).

    Time frame: baseline, 40 minutes post infusion, and 240 minutes post infusion

  5. The Clinician-Administered Dissociative States Scale (CADSS)

    The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92).

    Time frame: baseline, 40 minutes post infusion and 240 minutes post infusion

  6. Patient Rated Inventory of Side Effects (PRISE)

    The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section.

    Time frame: duration of study

07

Results

Posted Feb 8, 2017
Limitations and caveats
Sample size is small, increasing the likelihood of a false negative finding due to limited power. Unknown if the lack of significant separation between the treatment and control conditions at 24 h represents a true null finding or a false negative.

Participant flow

Participants were recruited through the inpatient psychiatric service or through an academic outpatient psychiatric clinic. All study treatments were performed at Mount Sinai Hospital between April 2012 and June 2014.

Participant flow — Overall Study
MilestoneKetamineMidazolam
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryChange in Beck Scale for Suicidal Ideation (BSSI)

Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.

Time frame:
baseline and 24 hours post infusion
Reported as:
Mean · units on a scale
Change in Beck Scale for Suicidal Ideation (BSSI)
units on a scaleKetamineMidazolam
Change in Beck Scale for Suicidal Ideation (BSSI)10.8 ± 8.514.0 ± 10.2
Statistical analysis
  • Ketamine vs Midazolam · t-test, 2 sided · p = 0.32
PrimaryChange in Beck Scale for Suicidal Ideation (BSSI)

Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.

Time frame:
baseline and 48 hours post infusion
Reported as:
Mean · units on a scale
Change in Beck Scale for Suicidal Ideation (BSSI)
units on a scaleKetamineMidazolam
Change in Beck Scale for Suicidal Ideation (BSSI)8.8 ± 8.315.3 ± 10.9
Statistical analysis
  • Ketamine vs Midazolam · t-test, 2 sided · p = 0.047
SecondaryMontgomery-Asberg Depression Rating Scale (MADRS)

The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.

Time frame:
up to 7 days post infusion
Reported as:
Mean · units on a scale
Montgomery-Asberg Depression Rating Scale (MADRS)
units on a scaleKetamineMidazolam
24 hours19.0 ± 15.526.2 ± 10.8
48 hours19.3 ± 13.528 ± 12.3
72 hours20.9 ± 14.524.1 ± 12.2
7 days21.7 ± 13.122.2 ± 13.1
Statistical analysis
  • Ketamine vs Midazolam · ANCOVA · p = 0.17 (Statistics are calculated by comparing 24-h scores using separate ANCOVAs and controlling for baseline severity.)
SecondarySuicidality Item of the MADRS (MADRS-SI)

The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide.

Time frame:
24 hours post infusion
Reported as:
Mean · units on a scale
Suicidality Item of the MADRS (MADRS-SI)
units on a scaleKetamineMidazolam
Suicidality Item of the MADRS (MADRS-SI)1.8 ± 1.93.3 ± 1.6
SecondaryThe Young Mania Rating Scale (YMRS)

An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.

Time frame:
baseline, 40 minutes post infusion, 240 minutes post infusion
Reported as:
Mean · units on a scale
The Young Mania Rating Scale (YMRS)
units on a scaleKetamineMidazolam
baseline0.0 ± 0.00.1 ± 0.3
40 minutes post infusion0.0 ± 0.00.3 ± 0.6
240 minutes post infusion0.2 ± 0.60.2 ± 0.6
SecondaryThe Brief Psychiatric Rating Scale (BPRS)

The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49).

Time frame:
baseline, 40 minutes post infusion, and 240 minutes post infusion
Reported as:
Mean · units on a scale
The Brief Psychiatric Rating Scale (BPRS)
units on a scaleKetamineMidazolam
baseline7.7 ± 1.127.7 ± 1.3
40 minutes post infusion9.9 ± 3.37.9 ± 1.8
240 minutes post infusion8.1 ± 1.67.0 ± 0.1
SecondaryThe Clinician-Administered Dissociative States Scale (CADSS)

The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92).

Time frame:
baseline, 40 minutes post infusion and 240 minutes post infusion
Reported as:
Mean · units on a scale
The Clinician-Administered Dissociative States Scale (CADSS)
units on a scaleKetamineMidazolam
baseline1.1 ± 2.64.0 ± 7.0
40 minutes post infusion17.1 ± 19.93.3 ± 3.1
240 minutes post infusion1.2 ± 1.91.3 ± 2.6
SecondaryPatient Rated Inventory of Side Effects (PRISE)

The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section.

Time frame:
duration of study
Reported as:
Number · events
Patient Rated Inventory of Side Effects (PRISE)
eventsKetamineMidazolam
Patient Rated Inventory of Side Effects (PRISE)2923

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine—5/12 (41.7%)12/12 (100%)
Midazolam—0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventKetamineMidazolam
HospitalizationsPsychiatric disorders4/120/12
DeathRespiratory, thoracic and mediastinal disorders1/120/12
Most frequent other events
Showing 10 of 15
Most frequent other events
EventKetamineMidazolam
HeadacheNervous system disorders7/123/12
Dizziness on standingNervous system disorders2/123/12
Nausea/VomitingGeneral disorders1/123/12
DiarrheaGeneral disorders0/123/12
AnxietyPsychiatric disorders2/122/12
Poor concentrationGeneral disorders2/121/12
Poor coordinationNervous system disorders2/120/12
General malaiseGeneral disorders2/120/12
RestlessnessGeneral disorders2/120/12
Dry mouthGeneral disorders0/122/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)KetamineMidazolamTotal
Mean45.8 ± 15.239.1 ± 10.642.4 ± 13.3
Gender
Gender(Participants)KetamineMidazolamTotal
Female8816
Male448
History of suicide attempt
History of suicide attempt(participants)KetamineMidazolamTotal
yes6915
no639
BSI score, baseline
BSI score, baseline(units on a scale)KetamineMidazolamTotal
Mean17.5 ± 7.217.9 ± 11.917.7 ± 9.7
MADRS score, baseline
MADRS score, baseline(units on a scale)KetamineMidazolamTotal
Mean35.2 ± 6.134.3 ± 4.134.8 ± 5.1
Primary Diagnosis
Primary Diagnosis(participants)KetamineMidazolamTotal
MDD6713
Bipolar disorder437
PTSD123
BPD101
Co-occurring disorders
Co-occurring disorders(participants)KetamineMidazolamTotal
MDD224
PTSD213
BPD101
Panic disorder314
SAD246
OCD336
GAD516
08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10027, United States
09

References and documents

Publications

  • Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec;45(16):3571-80. doi: 10.1017/S0033291715001506. Epub 2015 Aug 12. PubMed 26266877 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Jan 10, 2012
Start
Jan 2012
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Feb 8, 2017
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01507181
Lead sponsor
James Murrough
Responsible party
James Murrough (Principal Investigator, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Jan 10, 2012
Start date
Jan 2012
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Feb 8, 2017
Last update
Feb 8, 2017

Study contacts

James Murrough, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion